For full-year 2024 revenue, the company is providing guidance of approximately $54 million. For first quarter 2024 revenue, the company is providing a guidance range of $13.0 million to $13.5 million. For full-year 2024, the company believes its adjusted EBITDA will be better than negative $20 million. Given the company’s continued improved performance, we believe existing cash and cash equivalents are adequate to meet anticipated cash requirements into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XGN:
- XGN Earnings this Week: How Will it Perform?
- Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
- Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
